Fertility drugs and risk of ovarian cancer.
Fertility drugs and risk of ovarian cancer.
复制标题
生育药物和卵巢癌的风险。
DOI：
10.1093/oxfordjournals.humrep.a138217
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
Whittemore,AS
中科院分区：
文献类型：
--
作者：
Whittemore,AS
生育药物可能会增加女性患卵巢癌的风险，这一点令人不安，特别是对不孕夫妇和治疗他们的专业人员来说。最近，基于三项病例对照研究的联合分析，卵巢癌风险与生育药物既往治疗之间的正相关性报告提出了这种可能性（Whittemore et al.，1992年）。该关联被报道为生殖特征和外源性激素使用与卵巢癌风险相关的一般调查的一部分，该调查通过分析来自12项美国卵巢癌病例对照研究的综合数据获得。这项分析是由卵巢癌协作组（COCG）进行的，COCG是12项研究的主要研究者组成的联盟。作者还报道了卵巢癌风险与妊娠、哺乳和口服避孕药的使用之间的负相关性。卵巢癌风险与生育药物的使用之间的相关性所引起的痛苦对治疗不孕症的临床医生来说尤其严重，对他们来说，患者福利、患者咨询以及潜在的责任和专业地位问题都是值得关注的。因此，毫不奇怪，它的出版会促使与之有关联的个人，
The possibility that fertility drugs may increase a woman's risk of ovarian cancer is disturbing, particularly to infertile couples and the professionals who treat them. This possibility was raised recently by the report of a positive association between risk of ovarian cancer and prior treatment with fertility medications, based on the combined analysis of three case-control studies (Whittemore et al., 1992). The association was reported as part of a general investigation of reproductive characteristics and exogenous hormone use in relation to ovarian cancer risk, obtained by analysing the combined data from twelve US casecontrol studies of ovarian cancer. The analysis was conducted by the Collaborative Ovarian Cancer Group (COCG), a consortium of the Principal Investigators of the twelve studies. The authors also reported negative associations between ovarian cancer risk and pregnancy, lactation and use of oral contraceptives.The distress caused by the reported association between ovarian cancer risk and use of fertility drugs is particularly acute for clinicians treating infertility, for whom patient welfare, patient counselling, and issues of potential liability and professional status are of concern. It is therefore not surprising that its publication should prompt attempts by individuals affiliated with, sponsored